- Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
- Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
- Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
- Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
- Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones
- Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors
- Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference
- Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results
More ▼
Key statistics
As of last trade Beam Therapeutics Inc (BEAM*:MEX) traded at 450.00, 0.00% below its 52-week high of 450.00, set on Jan 30, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 448.80 |
---|---|
High | 450.00 |
Low | 448.80 |
Bid | 450.00 |
Offer | 750.00 |
Previous close | 393.31 |
Average volume | 0.00 |
---|---|
Shares outstanding | 82.31m |
Free float | 81.06m |
P/E (TTM) | -- |
Market cap | 1.88bn USD |
EPS (TTM) | -1.87 USD |
Data delayed at least 20 minutes, as of Jan 30 2024 11:30 GMT.
More ▼